Most cited papers in Diabetes Treatment and Management
What are the most cited papers in Diabetes Treatment and Management?
The most cited paper in Diabetes Treatment and Management is "Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man" (David Richard Matthews, J P Hosker, A. Rudenski et al., 1985), with 31,761 citations. Next come "Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation" (15,336) and "International Diabetes Federation 2017" (13,571).
Showing 50 of 100 papers. Every paper with more than 1,971 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man David Richard Matthews, J P Hosker, A. Rudenski et al. · Diabetologia | Jul 1985 | 31,761 |
| 2 | Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation K. G. M. M. Alberti, Paul Zimmet, WHO Consultation · Diabetic Medicine | Jul 1998 | 15,336 |
| 3 | International Diabetes Federation 2017 Ann M. Carracher, Payal H. Marathe, Kelly L. Close · Journal of Diabetes | 18 Jan 2018 | 13,571 |
| 4 | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine | 17 Sep 2015 | 12,282 |
| 5 | Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study IRENE M. STRATTON · BMJ | 12 Aug 2000 | 9,131 |
| 6 | Effects of Intensive Glucose Lowering in Type 2 Diabetes The Action to Control Cardiovascular Risk in Diabetes Study Group · New England Journal of Medicine | 6 Jun 2008 | 7,953 |
| 7 | Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Bruce Charles Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine | 12 Jun 2017 | 7,908 |
| 8 | 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes Rury R. Holman, Sanjoy Ketan Paul, Mary Angelyn Bethel et al. · New England Journal of Medicine | 10 Sep 2008 | 7,824 |
| 9 | Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine | 13 Jun 2016 | 7,629 |
| 10 | Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy Barry Morton Brenner, Mark Emmanuel Cooper, Dick de Zeeuw et al. · New England Journal of Medicine | 20 Sep 2001 | 7,554 |
| 11 | Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes The ADVANCE Collaborative Group · New England Journal of Medicine | 6 Jun 2008 | 7,469 |
| 12 | Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction John J.V. McMurray et al. · New England Journal of Medicine | 19 Sep 2019 | 7,135 |
| 13 | Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure John J.V. McMurray, Milton Packer, Akshay Suvas Desai et al. · New England Journal of Medicine | 30 Aug 2014 | 6,982 |
| 14 | Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Steven P. Marso, Stephen Charles Bain, Agostino Consoli et al. · New England Journal of Medicine | 16 Sep 2016 | 6,902 |
| 15 | Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine | 10 Nov 2018 | 6,466 |
| 16 | Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Vlado Perkovic et al. · New England Journal of Medicine | 14 Apr 2019 | 6,216 |
| 17 | Global aetiology and epidemiology of type 2 diabetes mellitus and its complications Yan Zheng, Sylvia H. Ley, Frank B. Hu · Nature Reviews Endocrinology | 8 Dec 2017 | 5,865 |
| 18 | Dapagliflozin in Patients with Chronic Kidney Disease Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter et al. · New England Journal of Medicine | 24 Sep 2020 | 5,523 |
| 19 | Role of AMP-activated protein kinase in mechanism of metformin action Gaochao Zhou, Robert P. Myers, Ying Li et al. · Journal of Clinical Investigation | 15 Oct 2001 | 5,473 |
| 20 | Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure Milton Packer et al. · New England Journal of Medicine | 28 Aug 2020 | 5,214 |
| 21 | Use and Abuse of HOMA Modeling Tara M Wallace, Jonathan Cummings Levy, David Richard Matthews · Diabetes Care | Jun 2004 | 5,184 |
| 22 | Intensive versus Conventional Glucose Control in Critically Ill Patients Nice-Sugar Study Investigators · New England Journal of Medicine | 24 Mar 2009 | 5,153 |
| 23 | Once-Weekly Semaglutide in Adults with Overweight or Obesity John P.H. Wilding, Rachel Louise Batterham, Salvatore Calanna et al. · New England Journal of Medicine | 10 Feb 2021 | 5,049 |
| 24 | Empagliflozin in Heart Failure with a Preserved Ejection Fraction Stefan D. Anker et al. · New England Journal of Medicine | 27 Aug 2021 | 4,854 |
| 25 | Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes William C. Duckworth, Carlos Abraira, THOMAS E. MORITZ et al. · New England Journal of Medicine | 17 Dec 2008 | 4,806 |
| 26 | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes Steven E. Nissen, Kathy Wolski · New England Journal of Medicine | 22 May 2007 | 4,695 |
| 27 | Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes Peter Gæde, Pernille Nygaard Vedel, Nicolai Balle Larsen et al. · New England Journal of Medicine | 29 Jan 2003 | 4,419 |
| 28 | Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial Jeremiah Stamler, Olga Vaccaro, James D. Neaton et al. · Diabetes Care | Feb 1993 | 4,107 |
| 29 | Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children Anshu Gupta, Jaime Uribarri · Hormone Research in Paediatrics | 2016 | 4,017 |
| 30 | Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) S. E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetologia | 19 Apr 2012 | 3,934 |
| 31 | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Daniel J. Drucker, Michael Albrecht Nauck · The Lancet | Nov 2006 | 3,921 |
| 32 | Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy David M. Nathan, John B. Buse, Mayer B. Davidson et al. · Diabetes Care | 22 Oct 2008 | 3,848 |
| 33 | Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Helen Martina Colhoun, D. J. Betteridge, Paul N. Durrington et al. · The Lancet | Aug 2004 | 3,798 |
| 34 | Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine | 14 Jun 2016 | 3,685 |
| 35 | Intensive Insulin Therapy in the Medical ICU Greet Van den Berghe, Alexander Wilmer, Greet Hermans et al. · New England Journal of Medicine | 2 Feb 2006 | 3,684 |
| 36 | Tirzepatide Once Weekly for the Treatment of Obesity Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad et al. · New England Journal of Medicine | 4 Jun 2022 | 3,648 |
| 37 | Biology of Incretins: GLP-1 and GIP Laurie L. Baggio, Daniel J. Drucker · Gastroenterology | May 2007 | 3,643 |
| 38 | Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Melanie J. Davies, David A. D’Alessio, JUDITH E. FRADKIN et al. · Diabetes Care | 5 Oct 2018 | 3,565 |
| 39 | Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events The ONTARGET Investigators · New England Journal of Medicine | 31 Mar 2008 | 3,538 |
| 40 | Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald et al. · New England Journal of Medicine | 2 Sep 2013 | 3,507 |
| 41 | Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes Peter Gæde, Henrik Lund‐Andersen, Hans‐Henrik Parving et al. · New England Journal of Medicine | 6 Feb 2008 | 3,489 |
| 42 | The Physiology of Glucagon-like Peptide 1 Jens Juul Holst · Physiological Reviews | Oct 2007 | 3,354 |
| 43 | Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Care | 19 Apr 2012 | 3,225 |
| 44 | International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes The International Expert Committee · Diabetes Care | 5 Jun 2009 | 3,211 |
| 45 | Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hertzel C. Gerstein et al. · The Lancet | 9 Jun 2019 | 3,173 |
| 46 | Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study Yasuo Ohkubo, Hideki Kishikawa, Eiichi Araki et al. · Diabetes Research and Clinical Practice | May 1995 | 3,105 |
| 47 | Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Care | 13 Dec 2014 | 3,098 |
| 48 | Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen Martina Colhoun et al. · New England Journal of Medicine | 11 Nov 2023 | 3,047 |
| 49 | Prediabetes: a high-risk state for diabetes development Ádám Gyula Tabák, Christian Herder, Wolfgang Rathmann et al. · The Lancet | Jun 2012 | 3,020 |
| 50 | Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association Sheri R. Colberg, Ronald J. Sigal, Jane Elizabeth Yardley et al. · Diabetes Care | 11 Oct 2016 | 3,003 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.